Possible Hepatotoxicity Associated With Daptomycin

@article{Mo2016PossibleHA,
  title={Possible Hepatotoxicity Associated With Daptomycin},
  author={Yoonsun Mo and Fletcher Nehring and A. Hydari N. Jung and Seth T. Housman},
  journal={Journal of Pharmacy Practice},
  year={2016},
  volume={29},
  pages={253 - 256}
}
Purpose To report a case of isolated daptomycin-induced acute liver injury without elevations in creatine kinase (CK) levels or kidney dysfunction. Summary A 49-year-old female with a history of pancreatitis, lupus, diabetes, congestive heart failure, hypertension, and chronic pain syndrome presented to the emergency department with alteration in mental status and acute liver failure. The patient had been treated with daptomycin for methicillin-resistant Staphylococcus aureus (MRSA… 
2 Citations

Figures and Tables from this paper

Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.

Clinicians should monitor these potential ADRs in patients receiving daptomycin by mining and evaluating the d aptomycin ADR signals from the US Food and Drug Administration Adverse Event Reporting System.

C-Locked Analogs of the Antimicrobial Peptide BP214

In a time-kill assay, this peptide showed a significant, concentration-dependent reduction in viable E. coli cells comparable to that seen for colistin, and the aim of the present work was to investigate how C-terminus-to-side chain macrocyclization and fatty acid modification affect the antimicrobial and hemolytic activity of BP214.

References

SHOWING 1-10 OF 17 REFERENCES

Daptomycin-Induced Acute Renal and Hepatic Toxicity Without Rhabdomyolysis

Although daptomycin is a well-tolerated antibacterial agent, clinicians should consider periodic monitoring of liver function and renal function tests to identify potential adverse effects.

Case Report and Cohort Analysis of Drug-Induced Liver Injury Associated with Daptomycin

A single-center retrospective cohort analysis of baseline and follow-up liver function panels from all admissions from 2008 to 2013 did not reveal any other cases of probable or definite drug-induced liver injury associated with daptomycin.

Daptomycin-induced rhabdomyolysis and acute liver injury

A role for liver function monitoring while receiving daptomycin is indicated, as well as the importance of promptly considering drug toxicities in acute and emergency care settings.

Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C.

The first case of creatinine phosphokinase (CPK) elevation with rhabdomyolysis developing during the co-administration of daptomycin and pegylated interferon a-2b and ribavirin is reported.

High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis

Higher-dose daptomycin may be an effective and safe alternative to SOC in the treatment of left-sided IE due to common Gram-positive pathogens.

Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.

The incidence of symptomatic CPK level elevation was within the range reported with lower doses of daptomycin and/or for shorter treatment durations, and well tolerated at a mean dose of 8 mg/kg for a median duration of 25 days.

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

The safety and efficacy of daptomycin were comparable with conventional therapy, and the frequency and distribution of adverse events were similar among both treatment groups.

Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects

Daptomycin was well tolerated when it was administered once daily at a dose as high as 8 mg/kg for 14 days, and there were no serious AEs and no pattern of dose-related events.

Moderate Liver Impairment Has No Influence on Daptomycin Pharmacokinetics

  • B. Dvorchik
  • Medicine, Biology
    Journal of clinical pharmacology
  • 2004
Evaluating the pharmacokinetic parameters of daptomycin in subjects between ages 18 and 80 years with moderately impaired hepatic function concluded that subjects with moderate hepatic impairment receiving d aptomycin do not require an adjustment in daptomecin dose or dose regimen.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

  • Catherine LiuA. Bayer H. Chambers
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
These guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system infections.